Progress of treatment of primary myelofibrosis
10.3760/cma.j.issn.1009-9921.2018.10.015
- VernacularTitle:原发性骨髓纤维化治疗研究进展
- Author:
Hailing NING
1
;
Xiulian ZHANG
Author Information
1. 山西医科大学第一医院血液科
- Keywords:
Primary myelofibrosis;
Ruxolitinib;
Treatment
- From:
Journal of Leukemia & Lymphoma
2018;27(10):628-631
- CountryChina
- Language:Chinese
-
Abstract:
Primary myelofibrosis (PMF) is a type of myeloproliferative neoplasms (MPN) with the worst prognosis in MPN. Immunomodulators, erythropoiesis-stimulating agents, cytoreductive drugs, splenectomy, etc. can significantly reduce the symptoms of patients, but can not improve the prognosis of patients. Allogeneic hematopoietic stem cell transplantation remains the only method that may cure PMF. The marketed JAK kinase inhibitor ruxolitinib and the hypomethylating agents, anti-fibrosis agents and telomerase inhibitorprovide new ideas for the treatment of PMF, made it possible to reverse the natural course of myelofibrosis. This paper reviews the progress of PMF therapy.
